This is an observational study to compare the utility of the novel aMRI approach in human brain to the standard of care imaging approach for diagnosing and assessing glioma. Tumor cells have altered metabolism compared to normal cells.This makes metabolic activity imaging useful for diagnosing and assessing neurological disease. However, current options for metabolic activity imaging are limited. Metabolic activity imaging is primarily conducted using positron emission tomography (PET) with a radioactive tracer called fludeoxyglucose F-18 (¹⁸FDG). A PET scan is a procedure in which a small amount of radioactive glucose (¹⁸FDG) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. PET imaging is very expensive and is usually much less available than other imaging techniques such as magnetic resonance imaging (MRI). MRI uses radiofrequency waves and a strong magnetic field to provide clear and detailed pictures of internal organs and tissues. While MRI is more available than PET, it isn't as useful in evaluating metabolic activity. Unlike standard MRI, the aMRI approach uses new ways of analyzing MRI images that provides information about tumor cell metabolic activity. Via direct comparison with a standard metabolic imaging approach, ¹⁸FDG PET, this clinical trial will assess the validity of aMRI as a metabolic imaging approach for evaluating neurological disease in patients with glioma.

开始日期2023-12-11

申办/合作机构

OHSU Knight Cancer Institute

[+1]

NCT05915728 / Completed临床3期

A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)

Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject contrast agent into a patient's vein to perform a so called "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve the evaluation.
The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd). Gadoquatrane is a new contrast agent under development with a lower amount of Gd needed per CE-MRI.
The main purpose of this study is to learn whether CE-MRI scans with gadoquatrane work better than MRI scans without the use of a contrast agent (GBCA). The researchers will compare the ability to detect known or suspected problems (except brain or spinal cord-related problems) with gadoquatrane-MRI scans to plain-MRI scans without the use of a contrast agent.
The participants will undergo 2 MRI scans, one with gadoquatrane and one with currently used GBCA. Both contrast agents will be injected into the vein.
Each participant will be in the study for between 6 and 42 days with up to 7 doctor visits.
At the start or during the study, the doctors and their study team will:
take blood and urine samples
do physical examinations
check blood pressure and heart rate
review the MRI scans obtained in the study and decide on the diagnosis
ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

开始日期2023-07-24

申办/合作机构

Bayer AG

NCT05915702 / Completed临床3期

A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of the Central Nervous System (CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)

Researchers are looking for a better way to help people with known or suspected brain or spinal cord-related problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject a contrast agent into a patient's vein to perform a so called "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve the evaluation.
The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd). Gadoquatrane is a new contrast agent under development with a lower amount of Gd needed per CE-MRI.
The main purpose of this study is to learn whether CE-MRI scans with gadoquatrane work better than MRI scans without the use of a contrast agent (GBCA). The researchers will compare the ability to detect brain and spinal cord-related problems in gadoquatrane-MRI scans to plain-MRI scans without the use of a contrast agent.
The participants will undergo 2 MRI scans, one with gadoquatrane and one with currently used GBCA. Both contrast agents will be injected into the vein.
Each participant will be in the study for between 6 and 42 days with up to 7 doctor visits.
At the start or during the study, the doctors and their study team will:
take blood and urine samples
do physical examinations
check blood pressure and heart rate
review the MRI scans obtained in the study and decide on the diagnosis
ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

开始日期2023-07-24

申办/合作机构

Bayer AG

100 项与钆特酸葡胺相关的临床结果

登录后查看更多信息

100 项与钆特酸葡胺相关的转化医学

登录后查看更多信息

100 项与钆特酸葡胺相关的专利（医药）

登录后查看更多信息

867

项与钆特酸葡胺相关的文献（医药）

2024-10-22·ENVIRONMENTAL SCIENCE & TECHNOLOGY

Formation of Nitrosamines from the Heterogeneous Reaction of Nitrous Acid and Organic Amines in Indoor Environments

Article

作者: Long, Shiqian ; Yang, Xin ; Yuan, Wenting ; Zhao, Wangchao ; Zheng, Guomao ; Zhu, Lei ; Xu, Jiwen ; Zhou, Li ; Ye, Jianhuai ; Zhang, Lifang ; Liu, Chenglin ; Jiao, Xiaoqiao ; Shen, Huizhong ; Yang, Bo ; Wang, Chen ; Huang, Weilin ; Fu, Tzung-May

Carcinogenic nitrosamines have been widely studied due to their risk to human health. However, the universality and evolutionary processes of their generation, particularly concerning their secondary sources, remain unclear at present. We demonstrated through laboratory flow tube experiments that corresponding nitrosamines were generated from heterogeneous reactions of nitrous acid (HONO) with five structurally diverse amines commonly found indoors, including diphenylamine (DPhA), dibenzylamine (DBzA), dioctylamine (DOtA), N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine (6PPD), and N-phenyl-1-naphthylamine (PANA). The heterogeneous reaction rate constants of DBzA and DOtA with HONO (∼70 ppb) were 1.21 × 10^-3 and 2.13 × 10^-3 min^-1 at 30% relative humidity (RH), resulting in a lifetime of 13.8 and 7.8 h. As compared to higher RH (∼80%), more nitrosamines were produced from the reaction of HONO with surface-sorbed DBzA, DOtA, 6PPD, and PANA at lower RH (30%), with product yields ranging from <0.1% to 0.5%. Furthermore, we observed the formation of nitroso-6PPDs and nitro-6PPDs during room air exposure of 6PPD in a genuine indoor environment, in addition to various other transformation products indicative of reactions of 6PPD with HONO, NOx, and ozone indoors. This study confirmed the universality of the heterogeneous reaction of surface-sorbed amine with HONO as a source of nitrosamines indoors.

2024-09-26·Journal of Physical Chemistry Letters

In Search of Covalency Measure of Gd(III)-Ligand Interactions

Article

作者: Starynowicz, Przemysław ; Siczek, Miłosz ; Janicki, Rafał

Experimental electron density distribution of the [C(NH₂)₃]₃[Gd(EDTA)F₂]·H₂O crystal was determined. The derived experimental and theoretical (DFT) topological parameters such as ∇²ρ_c, ρ_c, bond degree (BD), kinetics, and potential energy were used to study the nature of Gd-O, Gd-F, and Gd-N interactions. The natural charge of the Gd is 1.86; the natural configuration of the cation is [Xe]6s^0.134f^7.105d^0.83, and the covalency of the Gd-L bond is mainly connected with the transfer of charge from the sp^x ligand orbitals onto the 5d orbitals of the Gd cation. Simultaneously, the donation of charge onto the 6s and 4f orbitals occurs to a lesser extent. Moreover it was found that the donation of the ligand charges onto the Gd(III) is larger for compounds with a lower coordination number. The obtained topological parameters were analyzed in the context of the Gd(III) f-f transition properties, i.e., energy of the excited ^2S+1L_J states, Judd-Ofelt intensity parameters, and luminescence lifetimes, of 18 Gd(III) compounds with various O, N, and F donor ligands (DOTA, EDTA, CDTA, DTPA, NTA, EGTA, ODA, F^-, H₂O, and CO₃^2-). The calculated nephelauxetic β parameter may reflect the penetration degree of electron lone pairs of ligands inside the metal basin. Finally, it was found for the first time that the sum of the Gd(III)-L bond energy (∑E_GdL) is correlated with the position of the gravity center of the ⁸S_7/2 → ^2S+1L_J transitions and increase of covalency of the Gd(III)-L bonds is associated with decrease of their bond energy. The obtained results may shed light on chemical bonding in systems containing f-elements. Such subtle differences in the covalent contribution to the Ln-L or An-L bond may tune the selectivity of the partitioning processes of lanthanides and actinides.

2024-09-01·INVESTIGATIVE RADIOLOGY

Evaluation of the Contrast Enhancement Performance of Gadopiclenol for Magnetic Resonance Angiography in Healthy Rabbits and Pigs

Article

作者: Robert, Philippe ; Wintrebert, Mélody ; Arnould, Laurent ; Serfaty, Jean-Michel ; Adriaensen, Hans ; Hugon, Gaëlle

Objectives:

Unexpected accumulations of gadolinium in various organs were reported after the administration of gadolinium-based contrast agents, making desirable to reduce the dose while maintaining equivalent diagnostic performance. The aim of this study was to evaluate the contrast enhancement performance of high relaxivity gadopiclenol compared with gadoterate meglumine in abdominal contrast-enhanced magnetic resonance angiography (CE-MRA).

Materials and Methods:

In a first study in healthy rabbits, axial 3D gradient echo sequences were applied at 4.7 T to study arterial enhancement as a function of gadopiclenol dose (0.025, 0.05, 0.075, and 0.1 mmol Gd/kg) or gadoterate meglumine at 0.1 mmol Gd/kg (n = 5–6/group). The increase in signal-to-noise ratio (ΔSNR) in the aorta at the first pass was measured and compared. In a second, crossover study in 6 healthy pigs, abdominal CE-MRA sequences were acquired at 3 T with gadopiclenol at 0.05 mmol Gd/kg or gadoterate meglumine at 0.1 mmol Gd/kg at a 1-week interval. Quantitatively on the maximum intensity projection (MIP) images, the mean MIP SNR within the aorta of both groups was compared. Qualitatively, a blinded comparison of the angiograms was performed by an experienced radiologist to determine the preferred contrast agent.

Results:

In the rabbit, ∆SNR is linearly correlated with the gadopiclenol dose (P = 0.0010). Compared with gadoterate meglumine 0.1 mmol Gd/kg, an increase in the ∆SNR is observed after 0.05, 0.075, and 0.1 mmol Gd/kg of gadopiclenol (+63% P = 0.0731, +78% P = 0.0081, and +72% P = 0.0773, respectively), whereas at 0.025 mmol Gd/kg, ∆SNR is in the same range as with gadoterate meglumine 0.1 mmol Gd/kg (+15% P > 0.9999). In pigs, contrast enhancement after gadopiclenol at 0.05 mmol/kg is +22% superior to MIP SNR after gadoterate meglumine at 0.1 mmol Gd/kg (P = 0.3095). Qualitatively, a preference was shown for gadopiclenol images (3/6) over the gadoterate meglumine examinations (1/6), with no preference being shown for the remainder (2/6).

Conclusions:

First-pass CE-MRA is feasible with gadopiclenol at 0.05 mmol Gd/kg with at least the same arterial signal enhancement and image quality as gadoterate meglumine at 0.1 mmol Gd/kg.

项与钆特酸葡胺相关的新闻（医药）

2024-11-01

·药闻康策

官宣！第十批国采涉及62个大品种、263个品规

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策第十批集采终于官宣了！ 11月1日，联合采购办公室发布通知，第十批国家组织药品集中采购药品即将分阶段开展企业药品基础信息填报工作，第十批国家集采终于正式启动。第十批集采拟纳入62个品种、263个品规（以编号计），创历次集采之最。从销售规模看，62个品种2023年在中国公立医疗机构终端的销售额合计接近550亿元，其中超10亿大品种有20余个；纳入门槛提升至7家及以上，其中38个品种符合申报资格企业数达10家及以上，齐鲁制药、科伦药业、倍特药业等为主力。相信第十批集采开标后相关品种市场格局将迎来新一轮洗牌。 550亿市场激战在即 6个超10亿品种承压第十批集采或将成为历次最“卷”的一次国采。数据显示，拟纳入第十批集采的62个品种2023年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端的销售规模合计接近550亿元，其中超10亿大品种有20余个，6个品种销售额尚未突破1亿元。 62个品种销售额分布情况从治疗领域看，62个品种涵盖10个治疗大类，集中在心脑血管系统药物、全身用抗感染药物、消化系统及代谢药三大治疗领域，涉及的品种数分别达12、10、10个。数据显示，上述三个治疗大类2023年在中国公立医疗机构终端的销售额均超过1000亿元。在消化系统及代谢化药领域，包括4个糖尿病用药、1个矿物质补充剂、1个胃肠解痉药/抗胆碱药/胃动力药、1个治疗便秘的药物、1个治疗与胃酸分泌相关疾病的药物、1个维生素类及1个止吐药/止恶心药。拟纳入第十批集采的消化系统及代谢化药注：销售额低于1亿元用*代表 10个品种2023年在中国公立医疗机构终端的销售额合计超过100亿元，其中西格列汀口服常释剂型超20亿元，依帕司他口服常释剂型、利格列汀口服常释剂型、间苯三酚注射剂、复方聚乙二醇电解质散、注射用盐酸罗沙替丁醋酸酯等5个产品均超10亿元。 5大品种达20家以上齐鲁、倍特、科伦为主力从竞争情况看，西格列汀口服常释剂型为最“卷”品种，目前符合申报资格企业数已超过30家；此外，帕拉米韦注射剂、间苯三酚注射剂、乙酰半胱氨酸吸入剂、氨溴索口服液体剂均超20家，地氯雷他定口服液体剂、舒更葡糖注射剂达19家，艾司洛尔注射剂达18家。磷酸西格列汀片属于DPP-4抑制剂，用于改善2型糖尿病患者的血糖控制。该产品近年来在中国公立医疗机构终端的销售额逐年上涨，2023年突破20亿元，在口服糖尿病化药产品格局中排位第二。该原研药专利于2022年7月到期，正大天晴药业等企业的产品已于2022下半年开始上市销售，瓜分默沙东市场份额。目前有38家药企的磷酸西格列汀片以新注册分类报产，其中有32家药企（31家集团）已顺利获批并视同过评。近年来中国公立医疗机构终端磷酸西格列汀片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从企业纳入品种情况看，齐鲁制药、科伦药业、倍特药业、复星医药、石家庄四药、扬子江药业、石药集团、远大健康、华润医药、正大制药将为“主力军”，目前分别有22、19、18、18、17、17、15、13、12、10个过评品种在列。拟纳入品种数达10个及以上的国内企业齐鲁制药以22个品种领跑，包括11个注射剂、9个口服常释剂型及2个缓释控释剂型，其中瑞戈非尼片、马昔腾坦片、盐酸多柔比星脂质体注射液、米拉贝隆缓释片等为2024年新获批品种。科伦药业以19个品种排位第二，包括12个注射剂、6个口服常释剂型及1个缓释控释剂型等，其中瑞戈非尼片、艾地骨化醇软胶囊、己酮可可碱注射液、间苯三酚注射液等为2024年新获批品种。倍特药业、复星医药以18个品种并列第三，其中倍特药业有15个注射剂、3个口服常释剂型在列，重酒石酸去甲肾上腺素注射液、左西孟旦注射液、依帕司他片、重酒石酸间羟胺注射液、钆特酸葡胺注射液等为2024年新获批品种。附：报量品种竞争格局（数据截止时间：10月23日） (来源:医药经济报作者:茗瑶）药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购

2024-10-29

·北陆药业

北陆药业前三季度营收稳健增长，净利润同比涨11倍！

近日，北陆药业（300016）发布《2024年第三季度报告》。2024年前三季度，公司继续稳健经营，实现营业收入7.30亿元，同比增长12.30%；归属于上市公司股东的净利润为2,439.43万元，同比增长1156.34%；归属于上市公司股东的扣除非经常性损益的净利润为2,521.87万元，同比增长275.59%。在“二次创业”理念的引领下，公司积极践行“化药+中药”的业务模式，通过深化中成药领域布局、积极拥抱集采政策以及拓展海外市场等多措并举，推动公司业绩实现稳步增长。营业收入稳定增长公司基本盘稳固 2024年第三季度，北陆药业营业收入为2.56亿元，较上年同期增长20.77%，在此影响下，前三季度营业收入为7.30亿元，较上年同期增长12.30%。公司继续推动纳入集采的对比剂产品及降糖类产品的集采执标工作，并积极推广其他未纳入集采的产品销售，同时海外市场业务进展顺利，公司营业收入持续稳定增长。盈利能力强力回升战略转型初现成效相对于营业收入的稳定增长，公司净利润等相关指标的改善更加显著。2024年前三季度，北陆药业的归母净利润、扣非后的归母净利润分别为2,439.43万元、2,521.87万元，较上年同期分别增长1156.34%和275.59%。公司的盈利能力逐步恢复，公司经营回归良性运作，公司的战略转型初现成效。推动并购重组加大中成药板块布局公司一直重视“并购重组”业务，今年已通过并购的方式收购承德天原药业80%的股权，并将其纳入公司合并范围。公司目前拥有59个中成药产品，北陆药业的九味镇心颗粒和天原药业的金莲花颗粒作为公司两大销售额过亿的“黄金单品”，不仅具有良好的市场竞争力，同时为公司打造中药品牌提供了极强的助力。随着公司对天原药业的整合与赋能，公司的中药板块将成为公司业绩持续增长的重要驱动力，有望成为公司的“第二增长曲线”。积极提升研发效率研发成果逐渐落地报告期内，公司继续调整研发组织架构，提高研发效率，在对比剂制剂及原料药、中枢神经、内分泌、消化、维生素、外用制剂等领域布局，研发立项更加多元。全资子公司艾湃克斯积极落实公司的各项研发任务，并取得了阶段性的进展。年初至今，公司钆布醇注射液（15ml:9.0708g）、盐酸帕罗西汀肠溶缓释片、钆特酸葡胺注射液及原料药、硫酸钠等获批上市。钆贝葡胺注射液（10ml : 5.290g）、钆喷酸葡胺注射液（10ml：4.69g、12ml：5.63g）通过仿制药质量和疗效一致性评价。控股子公司海昌药业碘克沙醇化学原料药获批上市，生产车间通过 GMP 符合性检查。丰富的产品储备让公司未来经营业绩有了更多的增长可能性。

上市批准一致性评价并购财报

2024-10-25

·医药观澜

推进多肽放射性配体疗法研发，新锐获新一轮融资

▎药明康德内容团队报道 Starget Pharma近日宣布，该公司已从Cancer Focus Fund获得510万美元投资。Starget Pharma是一家临床阶段生物技术公司，致力于开发多肽类放射配体疗法。Cancer Focus Fund是一家独特的投资基金，由MD安德森癌症中心（MD Anderson）合作成立。根据新闻稿，本轮投资资金将用以支持肽类放射性配体疗法DOTA-PTR-58的1b期临床研究，用于治疗过度表达生长抑素受体3型（SSTR-3）的肿瘤，包括肉瘤、神经内分泌肿瘤（NET）、黑色素瘤和肝细胞癌。该试验将在MD Anderson和其他中心进行，并将于2025年初开始招募患者。 Starget Pharma正在利用其专有的Backbone Dynamics平台开发肽类放射性配体疗法。Backbone Dynamics是一种创新的多肽放射配体药物设计平台，使用专有的骨干环化技术（backbone cyclic）来创建具有更高稳定性、选择性和药代动力学的智能靶向放射配体。这些配体分子可以靶向潜在的肿瘤特异性靶点。 DOTA-PTR-58是一种超激动剂放射配体，其具有亚纳米级亲和力，可以选择性靶向SSTR-3，该受体在多种肿瘤类型中高表达，包括肉瘤、黑色素瘤、NET和肝细胞癌。与更常见的SSTR-2靶点不同，SSTR-3在正常组织中的表达较低，从而为相应的药物提供了更广泛的治疗窗口。DOTA-PTR-58包含了用Ga-68同位素成像和用Lu-177同位素、225Ac同位素治疗。在早期研究中，该分子表现出了较高的体内肿瘤摄取和内化、靶点选择性和显著的抗肿瘤活性。除了DOTA-PTR-58，Starget公司还在推进一系列靶向放射性疗法，用以治疗难治性癌症。根据Starget公司官网，该公司研发管线中还包括了其他三款放射性疗法，靶向CCK2R、GRPR等，针对的癌症类型包括了乳腺癌、肺癌、胃肠道间质瘤等。参考资料： [1] Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy. Retrieved Oct 23, 2024, from https://stargetpharma.com/starget-pharma-and-cancer-focus-fund-announce-5-1-million-investment-to-support-phase-1b-clinical-trial-of-novel-peptide-radioligand-for-precision-cancer-therapy/ 本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

放射疗法

100 项与钆特酸葡胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03355	钆特酸葡胺	V08CA02	DB09132

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
血管疾病	美国	Guerbet LLC	2013-03-20
造影剂	日本	Guerbet Japan KK	2000-09-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
中枢神经系统疾病	临床3期	阿根廷	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	奥地利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	巴西	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	智利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	法国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	德国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	意大利	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	韩国	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	西班牙	Guerbet LLC	2010-09-01
中枢神经系统疾病	临床3期	英国	Guerbet LLC	2010-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2020	N/A	急性肾小管坏死 \| 范可尼综合征	-	Dotarem (Gadobutrol)	選糧衊膚簾觸艱選選淵(膚觸壓製鹽憲膚壓願醖) = Renal tissue was characterized by tubular damage, pathologic lipid vacuolization, and diffuse mitochondrial toxicity 築網艱鹽糧廠遞簾顧衊 (醖憲餘齋願觸淵構廠鹽 ) 更多	不佳	2020-10-19
NCT01806740 (DCE-MRI, CTgov)	临床4期	晚期肝细胞癌	37	Gadoterate meglumine	糧餘膚夢蓋醖餘構壓觸(餘艱鏇鹽簾願膚鏇顧廠) = 觸夢壓鹹築襯餘鏇鬱鹹醖範膚繭艱鑰壓構製範 (憲鏇顧夢醖範製憲艱顧, 糧鏇廠廠壓餘繭齋遞衊 ~ 鏇顧遞網鹽積遞鹹獵餘) 更多	-	2019-08-08
NCT02411201 (CTgov)	临床4期	-	51	DOTAREM	廠繭鹹遞醖餘艱繭願襯(遞膚簾憲蓋廠鹹餘鹹遞) = 鹹鏇觸鏇衊衊夢鏇選鬱淵鬱選繭觸獵鬱鏇構齋 (鑰醖壓獵憲築構鹹襯觸, 淵艱窪製獵構衊淵淵獵 ~ 憲選窪窪獵夢鏇簾選構) 更多	-	2017-03-09
NCT02070380 (BENEFIT, CTgov)	临床4期	脑疾病	179	Dotarem (MultiHance 0.1 mmol/kg Arm (Reader 1))	鏇夢壓願壓醖壓蓋網餘(淵遞衊窪鏇製淵遞遞選) = 築網鑰積廠夢齋廠積願願範壓糧網廠鹽獵鹹窪 (積築夢鏇獵鹽獵繭憲鑰, 繭窪襯艱醖簾齋製範蓋 ~ 夢願艱遞糧範範鬱顧憲) 更多	-	2017-01-10
NCT02070380 (BENEFIT, CTgov)	临床4期	脑疾病	179	Dotarem (MultiHance 0.1 mmol/kg Arm (Reader 2))	鏇夢壓願壓醖壓蓋網餘(淵遞衊窪鏇製淵遞遞選) = 觸網糧鹽繭衊夢構壓觸願範壓糧網廠鹽獵鹹窪 (積築夢鏇獵鹽獵繭憲鑰, 構淵淵膚膚鬱鹹糧衊鏇 ~ 鹽襯顧積鏇鏇獵簾壓鏇) 更多	-	2017-01-10
NCT01211873 (SENTIO, CTgov)	临床3期	中枢神经系统疾病	416	Dotarem (gadoterate meglumine) (Dotarem (Gadoterate Meglumine ))	鹽鑰觸壓範觸鑰蓋窪壓(網夢選獵壓構選鑰鑰壓) = 簾構製壓艱襯鹹糧窪鹽襯衊襯窪繭構鏇壓襯製 (餘艱憲觸範鑰範鏇範鏇, 淵獵齋淵遞鑰繭積襯範 ~ 願壓窪遞廠膚齋壓餘簾) 更多	-	2014-05-29
NCT01211873 (SENTIO, CTgov)	临床3期	中枢神经系统疾病	416	Magnevist (gadopentetate dimeglumine) (Magnevist (Gadopentetate Dimeglumine))	鹽鑰觸壓範觸鑰蓋窪壓(網夢選獵壓構選鑰鑰壓) = 觸廠鑰鬱廠遞簾鹽齋壓襯衊襯窪繭構鏇壓襯製 (餘艱憲觸範鑰範鏇範鏇, 窪築餘顧壓範願繭製憲 ~ 簾積鬱壓構蓋簾廠選膚) 更多	-	2014-05-29
NCT01026389 (DALIA, CTgov)	临床4期	血管动脉疾病 \| 外周动脉疾病	189	Gadovist (Gadovist)	願壓廠簾鹹構鹹窪鬱蓋(艱淵鹹窪衊獵齋觸構鬱) = 鹽範願觸窪襯繭淵築蓋製鏇糧繭鏇積構餘構淵 (淵積築糧窪顧積艱積糧, 簾淵淵壓鹹窪觸鏇積鬱 ~ 壓醖製選鏇憲壓積繭選) 更多	-	2012-12-11
NCT01026389 (DALIA, CTgov)	临床4期	血管动脉疾病 \| 外周动脉疾病	189	Dotarem (Dotarem, Interventional)	願壓廠簾鹹構鹹窪鬱蓋(艱淵鹹窪衊獵齋觸構鬱) = 網願醖襯顧鏇選願襯鏇製鏇糧繭鏇積構餘構淵 (淵積築糧窪顧積艱積糧, 築鑰淵膚鬱觸積鹽顧齋 ~ 憲觸襯網選夢網壓遞鹹) 更多	-	2012-12-11